Аллопуринол

Quick links

Choose a section

Quick links to important sections

Advertisements

Аллопуринол

Selected form

Advertisements
Advertisements

Overview of Аллопуринол

What is Allopurinol?

Allopurinol is a widely used prescription medication that serves as a foundational therapy for managing conditions associated with high uric acid levels. It addresses the cause of the problem by limiting the body's ability to produce the substance that leads to crystal formation.

Property Description
Active ingredient Allopurinol (INN)
Form Oral tablets, Intravenous (IV) solution
Pharmacological class Xanthine Oxidase Inhibitor (XOI)
Common use Urate-lowering agent
Origin Synthetic (purine analog)

Allopurinol: Drug Overview and Identity

Allopurinol is primarily classified as an Antihyperuricemic Agent. Its general purpose is to effectively manage hyperuricemia—a condition where there are excessively high levels of uric acid in the blood. This medication is crucial for long-term management to prevent complications. Allopurinol belongs to the class of Xanthine Oxidase Inhibitors. This classification confirms that the medicine works by blocking a key enzyme in the body's metabolic process.

Composition and Pharmaceutical Type

The active substance in this medicine is Allopurinol (INN). It is a synthetic compound, specifically a structural analog of a natural purine base found in the body. The drug is most commonly available as oral tablets but is also formulated as an intravenous (IV) solution for specific, acute hospital needs. As a structural analog of hypoxanthine, its mechanism is highly specific to the purine catabolism pathway, differentiating it from treatments that rely on enhancing renal excretion.

General Therapeutic Purpose

The primary role of Allopurinol is to act as a potent urate-lowering agent. It achieves this by blocking the enzyme responsible for synthesizing uric acid, providing a sustained reduction in the overall uric acid concentration in the blood. The core benefit of this treatment is its ability to target the source of the problem, maintaining healthy uric acid levels to help prevent future complications. A typical use scenario for Allopurinol is the long-term, daily management required to keep serum uric acid levels below the crystallization threshold.

Advertisements

What side effects are possible with Аллопуринол?

Possible Side Effects and Safety Information

Allopurinol is associated with a risk of Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). These reactions are rare but can be life-threatening. The medication must be immediately discontinued at the first appearance of a skin rash or other signs of hypersensitivity.

Key risk factors for SCARs include pre-existing renal impairment and the presence of the *HLA-B58:01 allele**, which is notably more prevalent in patients of Han Chinese, Korean, and Thai descent. Dose reduction is required in patients with decreased renal function to mitigate the risk of adverse reactions due to accumulation of the active metabolite.

Common and Clinically Significant Adverse Reactions

Classification Adverse Reactions (Examples)
Common (Reported ge 1% of patients) Skin rash, nausea, vomiting, renal failure/insufficiency.
Uncommon Transient hepatotoxicity (liver injury), asymptomatic increase in liver enzymes, drowsiness.
Serious / Rare SJS, TEN, DRESS/Allopurinol Hypersensitivity Syndrome (AHS), Myelosuppression (e.g., agranulocytosis), clinical hepatotoxicity.

Allopurinol has been associated with effects on the hepatic, renal, dermatologic, and hematologic systems. Periodic monitoring of liver function (transaminases, alkaline phosphatase) is recommended, particularly during the early stages of therapy. Patients should exercise caution when performing activities requiring alertness, such as driving, due to the occasional occurrence of drowsiness.

Advertisements

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Allopurinol


Overdose Scope

Element Official Regulatory Statement
Documented overdose presentations The primary symptoms following massive acute ingestion include nausea, vomiting, diarrhoea, and dizziness.
Physiological systems affected Massive absorption results in considerable inhibition of xanthine oxidase activity.
Dose-related or exposure-related factors Acute ingestions of up to 22.5 grams have been reported; recovery followed general supportive measures.
Population-specific overdose notes There is an increased possibility of toxic effect when an overdose occurs in patients concurrently taking 6-mercaptopurine and/or azathioprine.
Emergency-response statements Management requires adequate hydration to maintain optimum diuresis to facilitate the excretion of the drug and its metabolites.
When immediate medical help is required Individuals are required to seek medical help right away and/or contact a Poison Control center.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification Regulatory documentation describes the effects of massive absorption but does not use a singular, defined severity classification.
Regulatory basis The information is derived from the Summary of Product Characteristics (SmPC) and FDA Prescribing Information.
Overdose-context constraints No specific antidote is known; treatment is focused on supportive management.

Resulting Overdose Structure

Official Overdose Statements:

  • Documented overdose presents with gastrointestinal symptoms and dizziness.
  • In the event of an overdose, individuals must seek medical help right away and management includes the use of general supportive measures.
  • Official management instructions require adequate hydration to promote diuresis, and haemodialysis may be considered for drug clearance.
  • The primary specific risk documented is the potential for increased toxicity of concomitant 6-mercaptopurine or azathioprine.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile based on documented manifestations from acute ingestion and the resulting massive inhibition of xanthine oxidase. This definition dictates that individuals must immediately seek medical attention, as treatment relies on supportive measures and procedures aimed at drug clearance. The profile emphasizes the specific regulatory alert concerning increased toxic effects for patients concurrently using certain cytotoxic drugs.

Advertisements

Therapeutic Uses of Аллопуринол

What Allopurinol Treats: Main Uses and Benefits

Allopurinol is commonly used to help with conditions presenting with systemic or localized discomfort, applied across domains where additional symptomatic support is needed. Its primary therapeutic areas are relevant in contexts involving heightened systemic burden.

The medicine generally assists with maintaining functional stability by being used for managing conditions characterized by periods of heightened symptoms, such as gout. It supports patients during episodes of heightened discomfort—including redness, swelling, and heat in the joints—contributes to easing the overall symptom load by addressing the systemic imbalance.

Allopurinol is considered relevant for easing symptoms linked to organ-specific functional stress. Its main therapeutic applications involve managing chronic symptoms of gout, addressing systemic imbalance during certain cancer therapies, and helping to prevent recurrent kidney stones. It provides supportive relief when symptoms interfere with routine activities.

“It may be part of symptomatic management in situations where patients experience difficult episodes.”

Quick Fact: Supports Management of Physical Discomfort (The medicine may help patients cope more steadily with symptom fluctuations.)

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Official Eligibility Profile

Allopurinol is subject to specific regulatory eligibility constraints that define which patient populations can use the medicine and under what conditions.

Eligibility Status Population/Condition
Contraindicated Patients with known hypersensitivity to allopurinol or any of its excipients, or those who have experienced a prior severe reaction (e.g., SJS/TEN).
Not Recommended Treatment of asymptomatic hyperuricemia.
Conditional Use/Caution Patients with renal or hepatic impairment, requiring dose reduction and careful monitoring.
Conditional Use/Caution Patients receiving azathioprine or mercaptopurine; the dose of the concomitant drug must be substantially reduced.

Age and Life Stage Constraints

  • Pediatric Use: Generally rarely indicated, primarily restricted to managing hyperuricemia related to cancer therapy (e.g., leukemia) and certain enzyme disorders.
  • Pregnancy: Use is not recommended unless the potential benefit justifies the risk to the fetus, as safety has not been established.
  • Lactation: Advised not to breastfeed during treatment, as the drug and its metabolite pass into human milk.

Genetic and Clinical Restrictions

Patients of Han Chinese, Thai, or Korean descent who are carriers of the *HLA-B58:01 allele are at a high risk of severe skin reactions, and use is generally not recommended** in this group unless no other therapeutic option exists.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Allopurinol's official interaction profile is characterized by its effect on the enzyme Xanthine Oxidase, which is essential for the metabolism of certain other medicines. The interaction information is categorized by regulatory bodies based on the severity and mechanism.

Pharmacokinetic Interactions and Restrictions

Co-administration with Mercaptopurine or its precursor, Azathioprine, is a clinically significant interaction. Allopurinol inhibits the enzyme required for the inactivation of these agents, which leads to increased plasma exposure of their active metabolites and potential toxicity. Regulatory constraints necessitate a significant dose reduction of Mercaptopurine or Azathioprine when these are combined with Allopurinol.

Another significant restriction involves Pegloticase, another urate-lowering agent. Co-administration of Allopurinol with Pegloticase is considered a contraindicated combination by regulatory agencies. Allopurinol therapy must be discontinued and not initiated during treatment with Pegloticase.

Furthermore, Allopurinol has been reported to prolong the half-life of the anticoagulant Dicumarol. Uricosuric agents, such as Probenecid, are known to increase the renal clearance of Allopurinol's active metabolite, oxipurinol, reducing the resulting degree of enzyme inhibition.

Pharmacodynamic and Timing Constraints

Concurrent use with Thiazide Diuretics carries an officially documented increased risk for hypersensitivity reactions, particularly in patients with decreased renal function. To avoid reduced absorption, administration of oral Allopurinol must be separated by two hours from antacids containing aluminum or calcium.

Advertisements

Mechanism of Action

How Аллопуринол Works


Core Mechanism: Inhibition of Xanthine Oxidoreductase

This mechanism focuses on the inhibition of the enzyme Xanthine Oxidoreductase (XOR), which is responsible for the final two steps of purine breakdown. Allopurinol acts as a mechanism-based inhibitor by being converted into its active metabolite, Oxypurinol, which then forms a stable complex with the enzyme's active site. This action fundamentally interrupts the biochemical cascade that leads to the synthesis of uric acid.


Metabolic Shift and Sustained Uric Acid Reduction

The enzymatic blockade causes a metabolic shift within the purine catabolism pathway, reducing the production of poorly soluble uric acid and instead allowing the accumulation and excretion of the more soluble precursors: hypoxanthine and xanthine. The resulting continuous lowering of serum uric acid (SUA) concentration below the saturation point is the mechanism that establishes a concentration below the physical chemical saturation point for monosodium urate, thereby influencing crystal formation and the stability of existing urate deposits.

Advertisements

Dosage and Administration Information

Allopurinol is administered as oral tablets for chronic, continuous management or as an intravenous infusion for acute hyperuricemia in specialized hospital settings. The oral regimen is structured as a titration process. Treatment typically commences with a low dose, such as 100 mg once daily, with the dose subsequently increased in 100 mg increments at weekly intervals until the desired therapeutic concentration of uric acid is attained. The maximum recommended oral dose for adults is 800 mg per day.

For practical administration, the tablets are generally taken following a meal to enhance gastrointestinal tolerability. If the total daily dose exceeds 300 mg, the dose is typically divided and taken multiple times per day. Adequate daily fluid intake, sufficient to achieve a urinary output of at least two liters, is a procedural requirement during therapy.

Administration rules for specific populations mandate dose reduction for patients with impaired kidney function, with initial doses often starting at 50 mg daily or less, followed by cautious adjustments. The intravenous form is initiated 24 to 48 hours prior to the start of chemotherapy when used for malignancy-associated hyperuricemia. In the event a dose is missed, it is generally advised to continue the regular schedule and not take a double dose to compensate.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Allopurinol

This overview describes the types of scientific research that have evaluated Allopurinol, the populations studied, and what the reported findings suggest, using neutral language and noting areas where evidence remains limited or uncertain. This information is drawn from authorized governmental and scientific sources and does not offer clinical advice.


Evidence for Use in Chronic Gout Management

This section will summarize the research base for long-term treatment of high uric acid levels, focusing on the randomized controlled trials (RCTs) and systematic reviews that measured biomarkers like serum urate, as well as clinical endpoints like the frequency of acute gout flares and tophus regression.

The primary research approach in this area involves Randomized Controlled Trials (RCTs), where Allopurinol was evaluated against a placebo (an inactive substance) or other study conditions. These studies monitored adult participants with chronic gout over defined time intervals. Researchers closely monitored biomarker shifts, such as the proportion of participants who reached a specific target level of serum urate (SU) concentration. Studies report that measurements of reductions in serum urate concentration were observed across populations studied. Research also highlights changes measured during the study period related to the patterns in acute flare frequency and the evolution of tophi size over extended follow-up.


Evidence for Use in Preventing High Uric Acid During Cancer Therapy

This part will detail the acute research studies, primarily RCTs, that have investigated Allopurinol's use in patients receiving chemotherapy to manage and prevent rapid increases in uric acid levels (prophylaxis against Tumor Lysis Syndrome), noting the specific metabolic and clinical endpoints studied.

Research in this area includes Randomized Controlled Trials (RCTs) and comparative studies involving adults and children with certain types of cancers who face a risk of developing a rapid increase in uric acid upon starting chemotherapy. These studies focused on a very short-term period, typically a few days around the start of cancer treatment. Studies monitored biomarker shifts related to the incidence and severity of Laboratory TLS (defined by specific changes in blood chemistry). Findings indicate patterns related to the control of serum uric acid levels during the acute treatment window in low-to-intermediate risk oncology patients.


What Is Still Uncertain About Allopurinol Research

The overall evidence landscape suggests that certain areas require more focused research or longer-term data. For gout management, there is limited information for long-term outcomes concerning major clinical endpoints, such as preventing long-term joint damage or cardiovascular events, with much of the current understanding relying on lower-certainty observational data. In the acute setting of Tumor Lysis Syndrome, the certainty remains low for the most critical clinical outcomes because sample sizes were modest for tracking rare events like acute kidney injury. Research does not determine whether an individual will respond similarly to the group patterns described in the studies.

Key Studies & References

  1. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Аллопуринол (FAQ)


Q: How quickly does Аллопуринол start working to lower uric acid?

According to official product information, a measurable reduction in uric acid levels in the blood and urine is often observed within 2 to 3 days of starting therapy. To achieve the long-term goal of a stable serum urate level, the time frame typically falls between 1 to 3 weeks.


Q: How long do I need to take Аллопуринол?

For chronic conditions like gout and high uric acid levels, regulatory guidance indicates that treatment is commonly considered a long-term therapy. This approach is often indicated to help maintain uric acid levels below the crystallization threshold. For other uses, such as managing the risk during certain cancer treatments, the duration is typically limited to the acute period.


Q: Can Аллопуринол cause changes to your skin?

Yes, skin changes are documented in official safety information. The most common skin-related event reported is a rash, which may present in various forms. Regulatory warnings also highlight the rare risk of severe cutaneous adverse reactions (SCARs).


Q: Is a rash a common side effect of Аллопуринол?

Yes, regulatory documents list a skin rash as a common adverse reaction, reported in 1% or more of patients in studies. Regulatory documents state that any appearance of a skin rash is a reason to seek medical evaluation immediately.


Q: Can I use over-the-counter pain relievers while taking Аллопуринол?

Official health body guidance indicates that allopurinol can generally be taken alongside common over-the-counter pain relievers. This includes drugs like Paracetamol (Acetaminophen) and anti-inflammatory medicines such as Ibuprofen. However, specific advice regarding drug combinations is determined by a healthcare professional.


Q: Are there any specific vitamins or supplements that interact with Аллопуринол?

Specific interactions with individual vitamins or supplements are not routinely detailed in core regulatory documents. Official guidance often notes that non-prescription products, including herbal remedies, are typically not assessed for interactions in the same way as prescription medicines.


Q: Is the main goal of Аллопуринол to prevent future gout attacks?

Yes, the primary therapeutic goal of allopurinol, as described in regulatory documents, is to reduce the production of uric acid. This method is intended to help reduce the risk of future recurrent gout attacks and related complications like kidney stones.


Q: Can I stop taking Аллопуринол once my uric acid levels are normal?

Regulatory information for chronic conditions such as gout often supports lifelong therapy to keep uric acid levels consistently stable. Discontinuation may lead to a subsequent increase in uric acid levels, which is associated with a higher risk of the condition returning.


Q: Are there any long-term side effects associated with Аллопуринол use?

Allopurinol is commonly used for long-term treatment. Regulatory documents detail a list of adverse effects, including rare but severe reactions like hypersensitivity syndromes, that can sometimes occur early in therapy. Periodic monitoring of liver and kidney function is recommended throughout long-term use.


Q: If I am taking diuretics (water pills), can I still take Аллопуринол?

Yes, but the combination requires careful management. Official documents highlight that concurrent use with thiazide diuretics may carry an increased risk for hypersensitivity reactions, especially if a patient also has reduced kidney function. Official prescribing information highlights the need for careful management.


Q: Are there different brands of Аллопуринол, and are they all the same?

Allopurinol is the chemical name of the active ingredient and is sold under various brand names globally. Medicines containing the same active ingredient are generally considered therapeutically equivalent by regulatory authorities.


Q: Is Аллопуринол the same as Colchicine, and what is the difference?

No, they are different medicines with distinct functions. Allopurinol is a xanthine oxidase inhibitor used for long-term prevention by lowering uric acid levels. Colchicine, in contrast, is used primarily to treat the pain and inflammation associated with an acute gout attack.


Q: Is it true that Аллопуринол can be used for kidney stones?

Yes, official labeling indicates that allopurinol is also used for the management of recurrent calcium oxalate kidney stones in patients who excrete high levels of uric acid daily.


Q: Is it possible to take Аллопуринол while pregnant?

Regulatory guidance advises that using allopurinol during pregnancy is not recommended unless the potential benefit is determined to outweigh the potential risk to the developing fetus, as safety has not been definitively established.


Q: Does Аллопуринол interact with blood thinners like Warfarin?

Yes, regulatory documents note that allopurinol has the potential to increase the effect of blood thinners such as Warfarin. Regulatory sources indicate that increased monitoring of blood clotting levels is necessary when these medications are used concurrently.


Q: Can people with liver disease use Аллопуринол?

The use of allopurinol requires caution in patients with pre-existing hepatic (liver) disease. Regulatory safety information recommends periodic monitoring of liver enzymes, particularly during the initial phase of treatment.


Q: Is Аллопуринол generally safe for older people?

Official drug labels mention that older adults may be more sensitive to the effects of allopurinol. Due to the common age-related decline in kidney function, a dose reduction is often necessary in older patients to minimize the risk of side effects.


Q: Do I need to change my diet when taking Аллопуринол?

The official FDA label specifically advises patients to increase their fluid intake to ensure a urinary output of at least two liters per day, which helps prevent renal stone formation. Some health bodies may also recommend complementary dietary adjustments, such as moderating purine intake.


Q: Will Аллопуринол help with the pain of a gout flare-up right now?

No, allopurinol is not indicated for treating the pain of an acute gout attack. Regulatory documents advise that initiating allopurinol during an acute flare is generally not recommended, as it is designed for chronic, not acute, use.


Q: Does Аллопуринол cause weight gain?

Weight gain is not commonly listed as a direct adverse reaction in regulatory documents. Conversely, some serious side effects have been associated with changes in appetite and resulting weight loss.


Q: Are there any warnings about combining Аллопуринол with herbal remedies?

Regulatory guidance generally advises caution regarding the combination of any prescription medicine with herbal remedies and supplements. This is because official sources indicate that these non-prescription products are typically not studied for their potential to interact with allopurinol.

Advertisements

How should Аллопуринол be stored and disposed of?

How to Store and Dispose of Allopurinol

Official regulatory guidelines define specific conditions for storing and disposing of Allopurinol to maintain its stability and ensure safety.

Storage Requirement Official Condition
Temperature Store at controlled room temperature, typically 20 to 25 C (68 to 77 F).
Protection Keep away from moisture, direct light, excess heat, and freezing.
Packaging Must be stored in the original container and kept tightly closed.
Child Safety Keep this medication out of sight and reach of children.
Injection Stability Reconstituted injection is stable for 10 hours at room temperature; do not refrigerate the mixed solution.

For disposal, unused or expired Allopurinol should be taken to a drug take-back location. Alternatively, the medication should be mixed with an undesirable substance, placed in a sealed bag, and disposed of in household trash. To protect the environment, the product must not be disposed of by pouring it down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Аллопуринол found in:

A-Z Index: